KRAS-targeting drug doubles survival in pancreatic cancer, fueling hope for broader use

Phase 3 results show the KRAS-targeting drug daraxonrasib doubles median survival in advanced pancreatic cancer (13.2 months vs 6.7 with chemotherapy), with FDA fast-track and expanded-access moves under way. The oral drug works by binding the KRAS-driven protein via cyclophilin A and appears less toxic than chemo, prompting optimism about its use in other KRAS-driven cancers, though it is not a cure and researchers are exploring where it fits in treatment sequences.